Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Literature DB >> 8092852

Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

M V Borobio¹, M Conejo, E Ramirez, A I Suarez, E J Perea.

Abstract

The in vitro activities of five new quinolones (clinafloxacin [CI-960 or PD-127391], BAY Y 3118, E-4868, E-5065, and E-5068) against 100 Bacteroides fragilis group bacterial isolates were compared with those of ciprofloxacin, ofloxacin, and sparfloxacin. Overall, E-5068 was the most active in vitro (MIC for 90% of isolates tested [MIC90], 0.25 microgram/ml); this was followed by clinafloxacin and BAY Y 3118 (MIC90, 0.5 microgram/ml). Ciprofloxacin, sparfloxacin, and ofloxacin were the least active (MIC90s, 64, 16, and 16 micrograms/ml, respectively). B. fragilis and Bacteroides caccae were more susceptible than the other members of the B. fragilis group to all of the quinolones tested.

Entities: Chemical Species

Mesh：

Substances：

Year: 1994 PMID： 8092852 PMCID： PMC188229 DOI： 10.1128/AAC.38.6.1442

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

16 in total

1. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

Authors: P C Fuchs; A L Barry; M A Pfaller; S D Allen; E H Gerlach
Journal: Antimicrob Agents Chemother Date: 1991-04 Impact factor: 5.191

2. Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors: D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal: Antimicrob Agents Chemother Date: 1990-12 Impact factor: 5.191

Review 3. Symposium on antimicrobial agents. The quinolones.

Authors: R C Walker; A J Wright
Journal: Mayo Clin Proc Date: 1987-11 Impact factor: 7.616

4. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

Authors: P C Appelbaum; S K Spangler; M R Jacobs
Journal: Antimicrob Agents Chemother Date: 1991-06 Impact factor: 5.191

Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

1. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.

2. Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Review 3. Symposium on antimicrobial agents. The quinolones.

4. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

5. The in-vitro activity of PD127,391, a new quinolone.

6. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.

7. Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.

8. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.

9. In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

10. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.

Review 1. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

2. In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

3. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

4. In vitro activities of newer quinolones against bacteroides group organisms.

5. Common Oral Medications Lead to Prophage Induction in Bacterial Isolates from the Human Gut.